Abbott Laboratories (ABT.US) announced that total revenue for the third quarter was $11.37 billion, slightly below the market expectation of $11.4 billion, as weakness in its diagnostics and nutrition businesses offset strong demand for its medical devices; adjusted earnings per share were $1.30, in line with expectations.
The company stated that it currently expects annual adjusted earnings per share to be between $5.12 and $5.18, compared to the previous expectation of $5.10 to $5.20

Abbott Laboratories announced that total revenue for the third quarter was $11.37 billion, slightly below the market expectation of $11.4 billion, as weakness in its diagnostics and nutrition businesses offset strong demand for its medical devices; adjusted earnings per share were $1.30, in line with expectations. The company stated that it currently expects annual adjusted earnings per share to be between $5.12 and $5.18, compared to the previous expectation of $5.10 to $5.20

"Performance" Abbott's revenue last quarter fell short of expectations, adjusting the full-year profit forecast